TL;DR
Orforglipron, sold as Foundayo, is an oral GLP-1 receptor agonist for weight management. Lilly reported that the FDA approved it on April 2, 2026. That announcement does not guarantee an immediate fill: patients still need clinician approval, a prescription, pharmacy stock, and an affordable price. We recommend checking the current FDA label and confirming the prescribed strength, cost, and availability with the dispensing pharmacy.
Orforglipron status: FDA approval, use, launch, and availability
Status checked: September 7, 2026
| Question | Current status |
|---|---|
| FDA status | Lilly reported FDA approval on April 2, 2026 |
| Approved use | Weight management; confirm the exact population in the current FDA label |
| Brand name | Foundayo |
| Approval date | April 2, 2026, according to Lilly’s announcement |
| Commercial launch date | Not confirmed in the supplied source material |
| Pharmacy availability | Depends on location, prescribed strength, and fill date |
Lilly announced Foundayo’s approval in a press release carried by BioSpace. Pharmacy Times subsequently discussed the approval in May 2026. We treat these as reports of the regulatory decision, not substitutes for the FDA approval record, prescribing information, or medication guide.
Approval and access are separate. Several steps must happen before treatment begins:
- The FDA approves the medicine for a defined use.
- The manufacturer distributes it commercially.
- A clinician determines that it is appropriate and issues a prescription.
- A pharmacy obtains the prescribed strength and processes the fill.
Insurance coverage and cost can create additional barriers even when stock is available.
Is orforglipron available yet?
As of September 7, 2026, Lilly has reported FDA approval, but the reviewed sources do not confirm a universal launch date or local pharmacy inventory. Same-day availability should not be assumed.
We recommend asking the pharmacy to search for both orforglipron and Foundayo. Confirm:
- Prescribed strength and quantity
- Current stock
- Expected restock date
- Cash price
- Insurance coverage or prior-authorization requirements
- Whether a new prescription is needed for the next strength
Neither we nor another telehealth service can guarantee stock. The usual process includes medical intake, clinician review, a prescribing decision, pharmacy processing, and inventory confirmation.
What is orforglipron approved to treat?
Lilly’s announcement describes Foundayo as approved for weight management. The current FDA label should be used to confirm the eligible age group, body mass index criteria, related health conditions, use limitations, and required lifestyle measures.
Trial findings do not create additional approved uses. In Lilly’s 2025 ATTAIN-2 announcement, participants had obesity or overweight and type 2 diabetes. At the highest studied dose, the reported average weight reduction was 10.5%, and average A1C fell by 1.8 percentage points. Those results do not, by themselves, establish a separate diabetes indication.
We recommend asking the prescribing clinician whether the proposed treatment matches the current label. Approval for weight management does not automatically mean the same product is approved to treat type 2 diabetes.
How orforglipron works and how the pill differs from peptide tablets
Orforglipron is an oral GLP-1 receptor agonist. Unlike peptide-based GLP-1 medicines, it is a small molecule designed to activate the GLP-1 receptor.
This structural difference can affect formulation, absorption, manufacturing, storage, and administration. It does not prove that one type of tablet is safer, more effective, or less expensive. Those questions require product-specific evidence and, for direct comparisons, appropriately designed comparative trials.
Small-molecule oral GLP-1 drugs
A small-molecule medicine does not require the same delivery approach as an oral peptide. Lilly’s approval announcement says orforglipron can be taken at any time of day without food or water restrictions.
Patients should still follow the current prescription label. Final FDA-approved instructions take priority over promotional materials, trial protocols, or directions written for another medicine.
A pill removes the injection step, but treatment still requires daily management. That may include:
- Taking the medicine every day
- Following a dose-escalation plan
- Monitoring side effects after dose changes
- Obtaining new prescriptions for different strengths
- Planning refills before travel
- Checking pharmacy inventory
We do not assume that daily tablets are easier than weekly injections for everyone. The right format depends on the approved use, dosing routine, tolerability, price, storage needs, and supply.
Peptide GLP-1 tablets
Peptides can be broken down in the digestive tract, so an oral peptide product may rely on a specialized formulation and detailed administration instructions.
Oral semaglutide is a familiar example. Depending on the product and current label, its instructions may include fasting, limited water, and a waiting period. Those directions should not be transferred to orforglipron.
The reverse also applies: orforglipron’s reported lack of food and water restrictions does not change another product’s instructions. When comparing oral medicines, we recommend reviewing:
- Approved use
- Dosing frequency
- Food, water, and timing rules
- Dose-escalation schedule
- Missed-dose directions
- Storage requirements
- Refill quantity
- Safety information
Orforglipron dosing, food rules, missed doses, and refills
The supplied sources do not contain Foundayo’s final starting dose, complete titration schedule, maintenance doses, maximum dose, or missed-dose cutoff. We will not fill those gaps with trial doses or instructions copied from another GLP-1 medicine.
Use the current FDA prescribing information, medication guide, and pharmacy label.
Starting dose and titration
Before starting or changing treatment, confirm each part of the dosing plan:
| Dosing step | What to confirm |
|---|---|
| Starting dose | The dose printed on the prescription label |
| Titration interval | The FDA-approved schedule and prescriber’s plan |
| Maintenance dose | The selected labeled dose based on clinical response |
| Maximum dose | The maximum stated in the current label |
| Restart after interruption | Instructions from the prescriber or pharmacist |
Titration is intended to help patients adjust to treatment, but it does not eliminate adverse effects.
Do not increase, split, combine, or restart doses without instructions. A dose change may require another prescription and a separate inventory check.
Daily administration and missed-dose rules
Lilly says orforglipron can be taken at any time of day without food or water restrictions. We recommend confirming that wording on the current pharmacy label before starting treatment.
The supplied sources do not establish the final missed-dose rule. If a dose is late or missed, consult the medication guide or pharmacist rather than doubling the next dose.
Daily tablets also require careful refill planning. Before each fill, check:
- Current strength
- Number of tablets remaining
- Date of the next planned dose change
- Whether another prescription is required
- Pharmacy stock
- Travel dates
- Storage instructions
A pharmacy may have one strength but not another. That can delay a planned dose increase even when the product is otherwise available.
Patients moving from a compounded product should not assume that it is interchangeable with an FDA-approved medicine. Those using compounded semaglutide can review these checks to make before a compounded semaglutide refill.
Orforglipron safety: warnings, side effects, interactions, and pregnancy
The current FDA label is the authority for orforglipron’s adverse reactions, contraindications, boxed warnings, precautions, interactions, and pregnancy guidance. The supplied sources do not include enough label text for us to reproduce those sections reliably.
The prescribing information should distinguish among:
- Boxed warnings: The FDA’s most prominent safety warnings, if applicable
- Contraindications: Circumstances in which the medicine must not be used
- Warnings and precautions: Risks requiring screening, monitoring, or action
- Adverse reactions: Side effects identified in studies or after approval
- Interactions: Other medicines or substances that may affect treatment
Safety information from semaglutide, tirzepatide, or another GLP-1 medicine should not be treated as Foundayo’s label.
Who should not take orforglipron?
Only the current prescribing information can define formal contraindications. Before prescribing, the clinician should review:
- Personal and family medical history
- Allergies and previous drug reactions
- Prescription and over-the-counter medicines
- Vitamins and supplements
- Current or previous GLP-1 treatment
- Insulin or sulfonylurea use
- Pregnancy, pregnancy plans, and breastfeeding
- Previous severe gastrointestinal symptoms
A warning is not always a contraindication. Some conditions prohibit treatment, while others require an individualized assessment.
Pregnancy planning also requires product-specific guidance. Patients should ask whether treatment needs to stop before a planned pregnancy and whether the label specifies a waiting period. Timing from another GLP-1 medicine should not be copied.
Side effects and drug interactions
The sources reviewed for this article do not provide final percentages or a complete product-specific list of common adverse reactions. Patients should use the medication guide and discuss expected effects with the prescriber or pharmacist.
Digestive effects may influence how some oral medicines are absorbed. Anyone taking drugs that require precise timing or monitoring should ask whether the treatment plan needs adjustment.
Seek urgent medical guidance for severe or persistent symptoms. Emergency care may be appropriate for trouble breathing, swelling of the face or throat, fainting, or other signs of a serious allergic reaction. Severe abdominal pain, persistent vomiting, inability to keep fluids down, or signs of dehydration also warrant prompt assessment.
Orforglipron price, cash cost, insurance, and monthly care total
Cost status checked: September 7, 2026
| Cost item | Current information |
|---|---|
| Manufacturer list price | Not provided in the supplied sources |
| Pharmacy cash price | Varies by pharmacy, strength, location, and date |
| Insured cost | Depends on plan coverage and benefit rules |
| Savings-program price | Depends on current terms and eligibility |
| Visit or telehealth fee | Set by the selected provider |
| Laboratory cost | Separate when required |
| Shipping | Separate when charged |
| Follow-up care | May involve an additional fee |
We do not recommend estimating orforglipron’s price from another GLP-1 medicine. Products can have different list prices, discounts, insurance policies, and pharmacy costs.
List price versus cash price
The list price is a manufacturer benchmark before rebates or discounts. It is not necessarily the patient’s bill.
The cash price is what a pharmacy quotes for a particular fill without using insurance benefits. It can vary by strength, quantity, pharmacy, location, and date.
The net patient cost is the amount due after eligible insurance benefits or discounts. Savings-program examples should not be presented as universal prices.
Savings, coverage, and hidden care costs
Savings programs may include eligibility rules, expiration dates, benefit limits, and restrictions based on insurance status. Patients should review the current terms rather than relying on an advertised starting price.
We suggest calculating the complete monthly cost:
| Monthly item | Patient’s amount |
|---|---|
| Orforglipron pharmacy price | $_____ |
| Visit or platform fee | $_____ |
| Required laboratory work | $_____ |
| Shipping | $_____ |
| Follow-up fee | $_____ |
| Estimated monthly total | $_____ |
Temi displays applicable service fees before a patient agrees to care. Medication, pharmacy, laboratory, and shipping charges are separate unless the checkout terms specifically include them.
Telehealth may provide a convenient route to clinician review, but it cannot guarantee a prescription, insurance coverage, a particular price, or pharmacy inventory. Existing patients can contact our prescription refill support.
Which GLP-1 drugs can be taken by mouth?
Oral GLP-1 medicines can differ in structure, approved use, dosing, administration, and safety information. The word “oral” does not make them interchangeable.
Approved oral GLP-1 options
The reviewed sources identify orforglipron and discuss semaglutide as part of the oral GLP-1 category. Current FDA labels should be checked for the precise products and approved uses available on the prescribing date.
| Category | Example | Form | Key distinction |
|---|---|---|---|
| Small-molecule oral GLP-1 | Foundayo, orforglipron | Tablet | Lilly reports approval for weight management and no food or water restrictions |
| Peptide oral GLP-1 | Oral semaglutide products | Tablet | Product-specific administration rules apply |
| Investigational oral GLP-1 | Development candidates | Varies | Not available as approved retail treatment without FDA authorization |
We do not rank orforglipron against oral semaglutide using results from separate trials. Populations, doses, endpoints, follow-up periods, and analysis methods may differ.
Oral versus injected GLP-1 care
An oral medicine removes injections, not the need for screening, titration, monitoring, renewals, or refill planning.
| Care factor | Daily oral treatment | Weekly injected treatment |
|---|---|---|
| Frequency | Follow the product’s daily schedule | Follow the product’s weekly schedule |
| Administration | May include timing, food, or water rules | Requires injection and device handling |
| Titration | Product-specific | Product-specific |
| Storage | Follow the package and label | May include refrigeration |
| Refill planning | Track tablets and dose changes | Track pens, vials, or weekly doses |
| Missed dose | Follow the oral product’s label | Follow the injected product’s label |
We view format as a fit question. Some patients prefer a daily tablet; others prefer a weekly injection. Approved use, safety, cost, supply, and routine matter more than the dosage form alone.
Oral GLP-1 pipeline 2026: active, delayed, and discontinued drugs
Pipeline reports can make experimental medicines appear closer to availability than they are. An investigational candidate is not an approved treatment and cannot be prescribed as a standard retail product.
The supplied material supports two dated points: Lilly reported positive Phase 3 orforglipron results in 2025, followed by reported FDA approval in 2026. It does not provide enough current evidence for us to assign reliable phases, delays, discontinuations, or launch dates to every other oral candidate.
| Program status | What it means |
|---|---|
| Active trial | The medicine remains investigational |
| Delayed | A previously expected milestone has moved |
| Discontinued | Development has stopped according to a current source |
| Deprioritized | The sponsor has reduced or redirected development |
| Unverified | No current conclusion should be drawn without a dated source |
| FDA approved | The medicine may be prescribed only for its labeled use, subject to availability |
Company timelines can change, and successful trials do not guarantee approval. We recommend checking a current trial registry, company announcement, and FDA record before treating any pipeline status as settled.
FAQ
How much will the orforglipron pill cost?
The supplied sources do not establish a universal monthly price. Cost depends on the pharmacy, prescribed strength, insurance, savings eligibility, visits, laboratory work, and shipping. Ask for each amount separately before starting treatment.
Is orforglipron available yet?
Lilly reported FDA approval on April 2, 2026, but local availability can vary. Approval, commercial distribution, and pharmacy stock are separate. Confirm the prescribed strength, quantity, price, and expected fill date with the pharmacy.
Which GLP-1 medicines can be taken orally?
Orforglipron is an oral small-molecule GLP-1 medicine. Oral semaglutide products are peptide-based tablets. Their approved uses and administration rules differ, so patients should follow the current label for the specific product prescribed.
Who should not take orforglipron?
The current FDA label defines the formal contraindications. A clinician should review medical history, allergies, medicines, previous GLP-1 reactions, pregnancy plans, and breastfeeding status before prescribing.
Can I switch from an injected GLP-1 to orforglipron?
A switch requires clinician guidance and may require a new prescription. Do not use an online dose conversion or overlap treatments without instructions. Confirm when to stop the previous medicine, when to begin the tablet, and whether the pharmacy has the required strength.
Get help with your next prescription
Use Temi to keep your medications and refill details in one place and request clinician review. A licensed clinician will decide whether treatment is appropriate, while the dispensing pharmacy will confirm the final price and available stock.
